Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

Completed · Not applicable · Has a placebo group

Conditions studied: HIV Infection

In brief

This is a 48 week randomized double-blind, placebo-controlled prospective cohort study of adolescents and young adults with HIV infection in the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) who are currently being treated with cART that includes tenofovir disoproxil fumarate (TDF) as one component of the regimen that includes at least three Food and Drug Administration (FDA)-approved antiretroviral (ARV) drugs for at least 180 days.

Key facts

Study ID

NCT01751646

Run by

University of North Carolina, Chapel Hill

People needed

214

Starts

2012-10-01

Expected to finish

2016-06-01

Last updated by the study team

2019-03-27

Who can join

Age: 16 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be considered eligible for enrollment, an individual must meet the criteria listed below at the time of randomization:
• NOTE: If the DXA scan is scheduled prior to randomization, all eligibility criteria must be met prior to performing the DXA scan.
• Age 16 years and 0 days to 24 years and 364 days;
• Behaviorally infected with HIV (e.g., sexual contact, injection drug use; not infected by perinatal transmission, blood transfusion, or at age younger than 9 years);
• HIV-1 infection as documented in subject's medical record by at least one of the following criteria:
• reactive HIV screening test result with an antibody based FDA-licensed assay followed by a positive supplemental assay (e.g., HIV-1 Western Blot, HIV-1 Indirect Immunofluorescence, Antibody Differentiation Assay (Multispot)); or
• positive HIV-1 DNA polymerase chain reaction (PCR) assay; or
• plasma HIV-1 quantitative RNA assay >1,000 copies/mL; or
• positive plasma HIV-1 RNA qualitative assay
• Subjects must have at least one documented HIV viral load that is below 200 copies/mL collected following initiation of TDF containing cART and greater than 90 days prior to randomization; no HIV viral load above 200 copies/mL if measured within the 90 days prior to randomization; and an HIV viral load obtained at screening that is below 200 copies/mL.
• Currently being treated for at least 180 days by the time of randomization with a TDF containing cART with at least 2 other FDA approved ARVs (NOTE: This may include a TDF-containing fixed drug combination medication);
• Negative serum hepatitis B surface antigen (HBsAg) at screening or by history within 4 weeks prior to screening (see section 7.1.3);
• Willingness and ability to remain on the same cART regimen for the duration of study participation;
• Willingness and ability to participate in the study, follow all study procedures for the duration of study participation, and provide written informed consent or assent with parental permission, if applicable; and
• For females of child-bearing potential, agreement to use a minimum of one proven-effective method of birth control and willingness to postpone pregnancy for the duration of study participation (see section 5.3.2 for permitted hormonal contraceptives)

You may not qualify if…

• To be considered eligible for enrollment, an individual must not meet any of the criteria listed below at the time of randomization:
• NOTE: If the DXA scan is scheduled prior to randomization, all eligibility criteria must be met prior to performing the DXA scan.
• Prior hypersensitivity to vitamin D;
• History of sarcoidosis, arteriosclerosis, renal stones, glomerulonephritis, interstitial kidney disease, nephrotic syndrome, hypercalcemia, osteoporosis and/or other bone diseases, clinical diagnosis of hypoparathyroidism or hyperparathyroidism;
• Lactation or pregnancy currently or within the past 24 weeks;
• Chemotherapy or radiation therapy for malignancy within the past 12 months;
• Known presence of GI disease that, in the opinion of the clinician, would interfere with study agent administration or absorption (e.g. Crohn's, Colitis);
• For subjects ≥ 18 years, confirmed creatinine clearance < 70 ml/min (estimated glomerular filtration rate (GFR) from SCr using Cockcroft and Gault (CG) equation) and for subjects <18 years, confirmed creatinine clearance < 70ml/min/1.73m2 (estimated GFR from SCr using Schwartz formula (see section 3.5). (Estimated GFR may be calculated using the formulae programmed on the ATN website);
• SCa > Upper Limit Normal (ULN) for local laboratory values (see section 7.1.3);
• Active Grade 3 or higher clinical or laboratory toxicity except atazanavir (ATV) associated indirect hyperbilirubinemia (see section 9.5.2.2);
• Weight is > 350 pounds (lbs) or 159 kilograms (kgs);
• Positive hepatitis C antibody by history or at screening (see section 7.1.3); and
• Use of any medications as specified in sections 5.3.1, 5.3.3 and 5.4.
• Females Only: Use of certain hormonal contraceptives as specified in the protocol.

Where it is running

• Children's Hopsital of Los Angeles — Los Angeles, California, United States
• University of Southern California - NICHD Westat Site — Los Angeles, California, United States
• Childrens National Medical Center — Washington D.C., District of Columbia, United States
• Children's Diagnostic and Treatment Center - NICHD Westat Site — Fort Lauderdale, Florida, United States
• University of Miami School of Medicine — Miami, Florida, United States
• University of South Florida — Tampa, Florida, United States
• Stroger Hospital and the CORE Center — Chicago, Illinois, United States
• Tulane Medical Center — New Orleans, Louisiana, United States
• Johns Hopkins University - NICHD Westat Site — Baltimore, Maryland, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Fenway Institute — Boston, Massachusetts, United States
• Wayne State University — Detroit, Michigan, United States
• Montefiore Medical Center — The Bronx, New York, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• St. Jude Childrens Research Hospital — Memphis, Tennessee, United States
• Baylor College of Medicine — Houston, Texas, United States
• San Juan City Hospital (Puerto Rico) - NICHD Westat Site — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.